A Phase 1 Trial of Amplimexon® (Imexon, Inj.) Plus Gemcitabine in Advanced, Previously Untreated Pancreatic Adenocarcinoma
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Determine maximally tolerated dose (MTD)
until MTD reached
Yes
Mark Zalupski, MD
Principal Investigator
University of Michigan
United States: Food and Drug Administration
AMP-004
NCT00327327
February 2004
October 2009
Name | Location |
---|---|
Arizona Clinical Research Center | Tucson, Arizona 85712 |
US Oncology Indiana | Indianapolis, Indiana 46227 |
US Oncology Albany, New York Oncology | Albany, New York 12208 |
US Oncology Orlando, Cancer Centers of FL | Ocoee, Florida 34761 |
Univ of Michigan | Ann Arbor, Michigan 48109 |
US Oncology Kettering | Kettering, Ohio 45409 |
Fox Chase Cancer Ctr. | Philadelphia, Pennsylvania 19111 |
US Oncology, Virginia Oncology Assoc | Norfolk, Virginia 23502 |
US Oncology Northwest, Northwest Cancer Specialists | Vancouver, Washington 98684 |